Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07545460 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started2026-07
View on ClinicalTrials.gov ↗

Amendment history

2026-06-26
Study Status, Eligibility, Contacts/Locations v1
Start date2026-04→2026-07
Study sites1→2
Eligibility criteria-217 characters
[...] tients with active central nervous system (CNS) metastases; Seizure-free status lasting >12 weeks with or without the use of antiepileptic drugs; No requirement for corticosteroid use to control cerebral edema; Radiographically stable status confirmed by two consecutive MRIs; Patients with a history of allergy to recombinant humanized [...]
2026-04-16
Original filing
This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with HER2-expressing platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
Trial Details
NCT Number NCT07545460
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Enrollment 404 participants
Start Date 2026-07
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-29